البحث عن طبيب

Yanyan Lou, M.D., Ph.D.

  1. Internist
  2. Oncologist
طلب موعد

المنشورات

  1. Abdelmoneim YM, Lou Y, Advani P, Khoor A, Sharma A, Parent EE. FES avid pulmonary adenocarcinoma and confounding ER+ breast carcinoma. Radiol Case Rep. 2025 Jan; 20 (1):801-804 Epub 2024 Nov 14
    View PubMed
  2. Luo Y, Gadd ME, Qie Y, Otamendi-Lopez A, Sanchez-Garavito JE, Brooks MM, Ulloa Navas MJ, Hundal T, Li S, Jones VK, Lou Y, Patel T, Dronca R, Kharfan-Dabaja MA, Dong H, Quinones-Hinojosa A, Qin H. Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1. Mol Ther Oncol. 2024 Dec 19; 32 (4):200891 Epub 2024 Oct 05
    View PubMed
  3. Luo M, Yang J, Schaffer AA, Chen C, Liu Y, Chen Y, Lin C, Diao L, Zang Y, Lou Y, Salman H, Mills GB, Ruppin E, Han L. Ancestral differences in anti-cancer treatment efficacy and their underlying genomic and molecular alterations. Cancer Discov. 2024 Nov 27 [Epub ahead of print]
    View PubMed
  4. Li Y, Zhao J, Li M, Dang Y, Yu E, Li J, Sun Z, Hussein U, Wen J, Abdelhameed AM, Mai J, Li S, Yu Y, Hu X, Yang D, Feng J, Li Z, He J, Tao W, Duan T, Lou Y, Li F, Tao C. RefAI: a GPT-powered retrieval-augmented generative tool for biomedical literature recommendation and summarization. J Am Med Inform Assoc. 2024 Sep 1; 31 (9):2030-2039
    View PubMed
  5. Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928 Epub 2024 Aug 13
    View PubMed
  6. Sacchi de Camargo Correia G, Lou Y, Manochakian R. Befotertinib: one more drug targeting EGFR-the more may be the merrier. Chin Clin Oncol. 2024 Aug 13 [Epub ahead of print]
    View PubMed
  7. Kimbrough EO, Marin-Acevedo JA, Drusbosky LM, Mooradian A, Zhao Y, Manochakian R, Lou Y. Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Cancers (Basel). 2024 Jun 27; 16 (13) Epub 2024 June 27
    View PubMed
  8. Rao S, Li S, Connor D, Fournier L, Manochakian R, Lou Y, Zhao Y. Disease monitoring using plasma-based circulating tumor DNA (ctDNA) assays in rare malignancies. J Clin Oncol. 2024; 42(suppl 16; abstr e15046).
  9. Pai TS, McKinley B, Seby R, Lewis JT, Komforti MK, Accurso J, Sonavane S, Baumgarten DA, Advani PP, Lou Y, Rao R. Metastatic Non-Small Cell Lung Cancer Mimicking Metaplastic Breast Cancer: A Case Report. JCO Precis Oncol. 2024 Jun; 8:e2400027
    View PubMed
  10. Luo J, Florez N, Donnelly A, Lou Y, Lu K, Ma PC, Spira AI, Ryan D, Husain H. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS(G12C)-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precis Oncol. 2024 Apr; 8:e2300644
    View PubMed
  11. Christopoulos P, Harel M, McGregor K, Brody Y, Puzanov I, Bar J, Elon Y, Sela I, Yellin B, Lahav C, Raveh S, Reiner-Benaim A, Reinmuth N, Nechushtan H, Farrugia D, Bustinza-Linares E, Lou Y, Leibowitz R, Kamer I, Zer Kuch A, Moskovitz M, Levy-Barda A, Koch I, Lotem M, Katzenelson R, Agbarya A, Price G, Cheley H, Abu-Amna M, Geldart T, Gottfried M, Tepper E, Polychronis A, Wolf I, Dicker AP, Carbone DP, Gandara DR. Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024 Mar; 8:e2300555
    View PubMed
  12. Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang J. Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers (Basel). 2024 Feb 26; 16 (5)
    View PubMed
  13. Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135. Epub 2024 Jan 25.
    View PubMed
  14. Sacchi de Camargo Correia G, Zhao Y, Manochakian R, Lou Y. The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer. Front Oncol. 2024; 14:1336546 Epub 2024 Feb 27
    View PubMed
  15. Li S, Manochakian R, Chen R, Patel J, Inampudi JV, Hiren KR, Zhao Y, Lou Y. Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy. Front Oncol. 2024; 14:1306311 Epub 2024 Feb 07
    View PubMed
  16. McKinley BJ, Pai TS, Wolf EB, Li S, Correia GSC, Zhao Y, Manochakian R, Lou Y. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis. Front Oncol. 2024; 14:1417175 Epub 2024 June 21
    View PubMed
  17. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
  18. Sacchi de Camargo Correia G, Pai T, Li S, Connor D, Zhao Y, Lou Y, Manochakian R. Immune-Related Adverse Events in Patients with Lung Cancer. Curr Oncol Rep. 2023 Nov; 25 (11):1259-1275 Epub 2023 Oct 02
    View PubMed
  19. Majeed U, Seegobin K, Lewis J, Li S, Zhao Y, Lou Y, Manochakian R. Lung Cancer in Patients With Lynch Syndrome: Association or Coincidence? Clin Lung Cancer. 2023 Nov; 24 (7):e237-e241 Epub 2023 May 31
    View PubMed
  20. Aslam FN, Manochakian R, Lou Y, Colon-Otero G, Sher T. Trends in participant race and sex reporting in lung cancer phase III clinical trials. Cancer Rep (Hoboken). 2023 Sep; 6 Suppl 1 (Suppl 1):e1856 Epub 2023 July 08
    View PubMed
  21. Li S, Lou Y, Manochakian R. When not having a tissue may not be an issue in advanced lung cancer. Chin Clin Oncol. 2023 Aug; 12 (4):32 Epub 2023 June 20
    View PubMed
  22. Majeed U, Li S, Seegobin K, Nassar A, Manochakian R, Zhao Y, Lou Y. First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non-Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report. JTO Clin Res Rep. 2023 Jul; 4 (7):100536 Epub 2023 June 15
    View PubMed
  23. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health. 2023 Jul; 5 (7):e404-e420 Epub 2023 May 31
    View PubMed
  24. Li S, de Camargo Correia GS, Wang J, Manochakian R, Zhao Y, Lou Y. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers (Basel). 2023 May 24; 15 (11)
    View PubMed
  25. Aakash Desai, Yash Ashara, Sagar Rakshit, Radhika Bansal, Ashley Potter, Rami Manochakian, Yanyan Lou, Yujie Zhao, Vinicious Ernani, Panos Savvides, Anna Schwecke, J. Nicole Moffett, Craig Hocum, Konstantinos Leventakos, Kaushal Parikh, Julian Molina, Aaron S. Mansfield, Anastasios Dimou. Sotorasib as 2nd line (2L) treatment for KRAS-mutated non-small cell lung cancer (NSCLC): Focus on hepatotoxicity and outcomes Journal of thoracic Oncology. 2023.
  26. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun. 2023 Feb 8; 14 (1):695 Epub 2023 Feb 08
    View PubMed
  27. Butts E, Gococo-Benore D, Pai T, Moustafa MA, Heng F, Chen R, Zhao Y, Manochakian R, Lou Y. Brief report: risk stratification following curative therapy for stage I NSCLC. Front Oncol. 2023; 13:1250315. Epub 2023 Aug 14.
    View PubMed
  28. Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Schwecke A, Moffett N, Hocum C, Leventakos K, Adjei A, Marks R, Molina J, Mansfield AS, Chen ZM, Dimou A. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023; 36:100743. Epub 2023 Jul 13.
    View PubMed
  29. Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Abraham AK, Healy J, Falchook GS. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec; 7 (6):100639 Epub 2022 Dec 06
    View PubMed
  30. Yin N, Liu Y, Weems C, Shreeder B, Lou Y, Knutson KL, Murray NR, Fields AP. Protein kinase Ciota mediates immunosuppression in lung adenocarcinoma. Sci Transl Med. 2022 Nov 16; 14 (671):eabq5931
    View PubMed
  31. Gao RW, Day CN, Yu NY, Bush A, Amundson AC, Prodduturvar P, Majeed U, Butts E, Oliver T, Schwecke AJ, Moffett JN, Routman DM, Breen WG, Potter AL, Rivera-Concepcion J, Hoppe BS, Schild SE, Sio TT, Lou Y, Ernani V, Ko S, Olivier KR, Merrell KW, Garces YI, Manochakian R, Harmsen WS, Leventakos K, Owen D. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab. Lung Cancer. 2022 Aug; 170:58-64 Epub 2022 June 13
    View PubMed
  32. Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, P Zandberg D, Kalebasty AR, Atkinson V, Adjei AA, Seetharam M, Birnbaum A, Weickhardt A, Ganju V, Joshua AM, Cavallo R, Peng L, Zhang X, Kaul S, Baughman J, Bonvini E, Moore PA, Goldberg SM, Arnaldez FI, Ferris RL, Lakhani NJ. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. 2022 Apr; 10 (4)
    View PubMed
  33. Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y, Mody K, Moreno-Aspitia A, Swift MD, Virk A, Bharucha AE, Marquez CP, Patel TC, Gores GJ, Knutson KL. Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clin Proc Innov Qual Outcomes. 2022 Apr; 6 (2):120-125 Epub 2021 Dec 13
    View PubMed
  34. Hong DS, Rixe O, Chiu VK, Forde PM, Dragovich T, Lou Y, Nayak-Kapoor A, Leidner R, Atkins JN, Collaku A, Fox FE, Marshall MA, Olszanski AJ. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 Feb 1; 28 (3):479-488 Epub 2021 Nov 09
    View PubMed
  35. Ye Y, Zhang Y, Yang N, Gao Q, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Profiling of immune features to predict immunotherapy efficacy. Innovation (Camb). 2022 Jan 25; 3 (1):100194 Epub 2021 Dec 02
    View PubMed
  36. Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X, Liu H, Han L. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J Immunother Cancer. 2022 Jan; 10 (1)
    View PubMed
  37. Sh Ahmed O, Mahadevia H, Manochakian R, Zhao Y, Salinas M, Khoor A, LeGout J, Lou Y. A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab. Case Rep Oncol. 2022 Sep-Dec; 15(3):1063-1073. Epub 2022 Nov 28.
    View PubMed
  38. Joe R, Matsumura Y, Siddiqui A, Foulks J, Beg M, Thompson J, Yamamoto N, Spira A, Sarantopoulos J, Melear J, Lou Y, Lebedinsky C, Li J, Watanabe A, Warner S. The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models. European Journal of Cancer. 2022; 174:S57-8
  39. Shi H, Seegobin K, Heng F, Zhou K, Chen R, Qin H, Manochakian R, Zhao Y, Lou Y. Genomic landscape of lung adenocarcinomas in different races. Front Oncol. 2022; 12:946625 Epub 2022 Sept 28
    View PubMed
  40. Pal K, Hussain T, Xie H, Li S, Yang P, Mansfield A, Lou Y, Chowdhury S, Mukhopadhyay D. Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. Front Oncol. 2022; 12:959500 Epub 2022 Aug 22
    View PubMed
  41. Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst. 2021 Oct 1; 113 (10):1396-1404
    View PubMed
  42. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021 Jul 8; 14 (1):108 Epub 2021 July 08
    View PubMed
  43. Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Mishra V, Schroder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul 1; 27 (13):3630-3640 Epub 2021 Apr 05
    View PubMed
  44. Wiest NE, Tzou KS, Olson MT, Herchko SM, Bajalia EM, Thiel DD, Lou Y, Zhao Y, Manochakian R. Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature. Clin Case Rep. 2021 Jun; 9 (6):e04278 Epub 2021 June 10
    View PubMed
  45. Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol. 2021 May 12; 14 (1):78
    View PubMed
  46. Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021 Mar 19; 14 (1):45
    View PubMed
  47. Zhou K, Shi H, Chen R, Cochuyt JJ, Hodge DO, Manochakian R, Zhao Y, Ailawadhi S, Lou Y. Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Netw Open. 2021 Jan 4; 4 (1):e2032276 Epub 2021 Jan 04
    View PubMed
  48. Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Front Oncol. 2021; 11:750657 Epub 2021 Dec 01
    View PubMed
  49. Shi H, Zhou K, Cochuyt J, Hodge D, Qin H, Manochakian R, Zhao Y, Ailawadhi S, Adjei AA, Lou Y. Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. Front Oncol. 2021; 11:773958 Epub 2021 Dec 10
    View PubMed
  50. Alhaj Moustafa M, Jiang L, Kuhlman JJ, Jones J, Lou Y, Sokumbi O, Tun HW. BRAF p.V600E associated poly-neoplastic syndrome. Rare Tumors. 2021; 13:20363613211012929 Epub 2021 Apr 27
    View PubMed
  51. Wiest N, Majeed U, Seegobin K, Zhao Y, Lou Y, Manochakian R. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Front Oncol. 2021; 11:751209 Epub 2021 Nov 16
    View PubMed
  52. Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020 May 24; 13 (1):58
    View PubMed
  53. Duma N, Idossa DW, Durani U, Frank RD, Paludo J, Westin G, Lou Y, Mansfield AS, Adjei AA, Go RS, Ailawadhi S. Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May; 21 (3):e115-e129 Epub 2019 Aug 30
    View PubMed
  54. Singh R, Lehrer EJ, Ko S, Peterson J, Lou Y, Porter AB, Kotecha R, Brown PD, Zaorsky NG, Trifiletti DM. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. Radiother Oncol. 2020 Mar; 144:165-179 Epub 2019 Dec 05
    View PubMed
  55. Seegobin K, Majeed U, Lou Y, Zhao Y, Manochakian R. Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature. SAGE Open Med Case Rep. 2020; 8:2050313X20966895. Epub 2020 Oct 24.
    View PubMed
  56. Pan D, Zhou D, Cai W, Wu W, Tan WL, Zhou C, Lou Y. Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma. BMC Immunol. 2019 Nov 13; 20 (1):43
    View PubMed
  57. Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist. 2019 Nov; 24 (11):e1148-e1155 Epub 2019 Apr 29
    View PubMed
  58. Krencz I, Sebestyen A, Papay J, Lou Y, Lutz GF, Majewicz TL, Khoor A. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma. Hum Pathol. 2019 Nov; 93:74-80 Epub 2019 Aug 24
    View PubMed
  59. Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano-Muller AE, Mashadi-Hossein A, Warren S, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clin Cancer Res. 2019 Jul 15; 25 (14):4422-4430 Epub 2019 Feb 26
    View PubMed
  60. Lou Y, Marin-Acevedo JA, Vishnu P, Manochakian R, Dholaria B, Soyano A, Luo Y, Zhang Y, Knutson KL. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy. 2019 May; 11 (7):577-584
    View PubMed
  61. Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin SH, Xia Y, Lin C, Yang L, Mills GB, Liang H, Han L. Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nat Metab. 2019 Apr; 1 (4):431-444 Epub 2019 Mar 18
    View PubMed
  62. Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018 Nov 23; 6 (1):129
    View PubMed
  63. Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, Ko SJ, Thomas M, Johnson MM, Patel NM, Miller RC, Adjei AA, Ailawadhi S. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018 Oct; 7 (10):4932-4942 Epub 2018 Sept 02
    View PubMed
  64. Duma N, Azzouqa AG, Yadav S, Hoversten K, Reed C, Sitek AN, Lou Y, Molina J, Halfdanarson T, Leventakos K, Joseph RW, Manochakian R, Dronca R. Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy. Ann Oncol. 2018 Oct; 29 Suppl 8:viii432
    View PubMed
  65. Cai W, Zhou D, Wu W, Tan WL, Wang J, Zhou C, Lou Y. MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics. 2018 Aug 3; 19 (1):582 Epub 2018 Aug 03
    View PubMed
  66. Xiang Y, Ye Y, Lou Y, Yang Y, Cai C, Zhang Z, Mills T, Chen NY, Kim Y, Muge Ozguc F, Diao L, Karmouty-Quintana H, Xia Y, Kellems RE, Chen Z, Blackburn MR, Yoo SH, Shyu AB, Mills GB, Han L. Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. J Natl Cancer Inst. 2018 Apr 1; 110 (4):379-389
    View PubMed
  67. Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C, Guo AY, Zhou B, Wang L, Chen Z, Takahashi JS, Mills GB, Yoo SH, Han L. The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. Cell Syst. 2018 Mar 28; 6 (3):314-328.e2 Epub 2018 Mar 07
    View PubMed
  68. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018 Mar 15; 11 (1):39
    View PubMed
  69. Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12; 11 (1):8
    View PubMed
  70. Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. Pharmacoeconomics. 2017 Aug; 35 (8):831-844
    View PubMed
  71. Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017 Feb; 20 (2):140-150 Epub 2016 Oct 03
    View PubMed
  72. Dholaria B, Hammond W, Shreders A, Lou Y. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016 Dec 9; 9 (1):138 Epub 2016 Dec 09
    View PubMed
  73. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 Jul 15; 22 (14):3630-42 Epub 2016 Feb 05
    View PubMed
  74. Gelbard A, Huang X, Dai Z, Lou Y, Liu C, Manisha S, Yared H, Martin-Orozco N, Kimberly S, Zal T, Zal A, Li H, Stephanie W, Esashi ?E, Liu Y, Overwijk W. Direct Negative Feedback Regulation of Type I Interferon Production in Plasmacytoid Dendritic Cells The Journal of Immunology. 2016.
  75. Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, Luthra R, Wistuba II, Zuo Z, Tsao AS. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2016 Mar; 17 (2):e5-11 Epub 2015 Nov 17
    View PubMed
  76. Qu J, Yu H, Li F, Zhang C, Trad A, Brooks C, Zhang B, Gong T, Guo Z, Li Y, Ragupathi G, Lou Y, Hwu P, Huang W, Zhou D. Molecular basis of antibody binding to mucin glycopeptides in lung cancer. Int J Oncol. 2016 Feb; 48 (2):587-94 Epub 2015 Dec 18
    View PubMed
  77. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med. 2013 Apr; 19(4):465-72. Epub 2013 Mar 03.
    View PubMed
  78. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizee G, Hwu P. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403. Epub 2012 Nov 30
    View PubMed
  79. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizee G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012 Oct 15; 72(20):5209-18. Epub 2012 Aug 20.
    View PubMed
  80. Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizee G, Zhou D, Overwijk WW, Hwu P. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012 Apr; 35(3):276-82.
    View PubMed
  81. Lou Y, Liu C, Lizee G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
    View PubMed
  82. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizee G, Hwu P. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010 Nov 15; 16(22):5458-68. Epub 2010 Oct 1
    View PubMed
  83. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, Kwak LW. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood. 2009 Nov 5; 114 (19):4142-9 Epub 2009 Sept 11
    View PubMed
  84. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009 Jun 15; 182(12):7398-407.
    View PubMed
  85. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118 (3):1165-75
    View PubMed
  86. Liu S, Lizee G, Lou Y, Liu C, Overwijk WW, Wang G, Hwu P. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21.
    View PubMed
  87. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol. 2007 Feb 1; 178(3):1534-41.
    View PubMed
  88. Xia C, Zhou D, Liu C, Lou Y, Yao Q, Zhang W, Wang PG. Thio-isoglobotrihexosylceramide, an agonist for activating invariant natural killer T cells. Org Lett. 2006 Nov 23; 8(24):5493-6.
    View PubMed
  89. Hu B, Wei Y, Tian L, Zhao X, Lu Y, Wu Y, Yao B, Liu J, Niu T, Wen Y, He Q, Su J, Huang M, Lou Y, Luo Y, Kan B. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. J Immunother. 2005 May-Jun; 28(3):236-44.
    View PubMed
  90. Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY, Wen YJ, Niu T, Xiao F, Lou YY, Tan GH, Deng HX, Li J, Yang JL, Mao YQ, Kan B, Wu Y, Li Q, Wei YQ. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology. 2005; 69(1):81-7. Epub 2005 Aug 02.
    View PubMed
  91. Lou Y, Wang G, Lizee G, Kim GJ, Finkelstein SE, Feng C, Restifo NP, Hwu P. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004 Sep 15; 64(18):6783-90.
    View PubMed
  92. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, Kim G, Leonard WJ, Hwu P. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003 Dec 15; 63(24):9016-22.
    View PubMed
  93. Liu J, Wei Y, Yang L, Zhao X, Tian L, Hou J, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su J, Lou Y, He Q, Wen Y, Yang J, Kan B, Mao Y, Luo F, Peng F. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood. 2003 Sep; 102(5):1815-23.
  94. He Q, Wei Y, Zhao X, Tian L, Su J, Yang L, Kan B, Lou Y, Huang M, Xiao F, Liu J, Hu B, Luo F, Jiang Y, Wen Y, Deng H, Li J, Niu T, Yang J. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. Journal of Biological Chemistry. 2003 Jun; 278(24):21831-6.
  95. Su J, Wei Y, Tian L, Zhao X, Yang L, He Q, Wu Y, Lu Y, Lou Y, Hu B, Niu T, Wen Y, Xiao F, Deng H, Li J, Kan B. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Research. 2003 Feb; 63(3):600-7.
  96. Xiao F, Wei Y, Yang L, Zhao X, Tian L, Yuan S, Din Z, Lou Y, Liu J, Hu B, Luo F, Jiang Y, Wen Y, Deng H, Li J. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Therapy. 2002 Sep; 9(18):1207-13.
  97. Lou Y, Wei Y, Yang L, Zhao X, Tian L, Lu Y, Wen Y, Liu F, Huang M, Kang B, Xiao F, Su J, He Q, Xie X, Mao Y, Lei S, Liu J, Lou F, Zhou L, Peng F, Jiang Y, Hu B. Immunogene therapy of tumor with vaccine based on the ligand binding domain of chicken homologous integrin beta3. Immunological Investigations. 2002 Feb; 31(1):51-69.
  98. Wei Y, Huang M, Yang L, Zhao X, Tian L, Lu Y, Su J, Niu T, Kan B, Mao Y, Liu F, Wen Y, Luo F, Zhou L, Peng F, Jiang Y, Xiao F, Lou Y, Xie X, Li Q, Wu Y, Ding Z, Hu B, Hu M, Zhang W. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proceedings of the National Academy of Sciences USA. 2001 Sep; 98(20):11545-50.
  99. Wei Y, Wang Q, Zhao X, Yang L, Tian L, Lu Y, Kan B, Huang M, Lou Y, Xiao F, He Q, Shu J, Xie X, Mao Y, LeiS, Luo F, Zhou L, Liu C, Zhou H, Jiang Y, Peng F, Yuan L, Li Q, Wu Y, Liu J. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nature Medicine. 2000 Oct; 6(10):1160-6.